Zentiva proposes EUR 10 per share offer for APONTIS PHARMA

FRANKFURT – Zentiva AG, a significant player in the generic drugs market in Germany, has announced a voluntary public purchase offer for all outstanding shares of APONTIS PHARMA AG at EUR 10.00 per share in cash. This offer represents a premium of 52.9% over the closing price of APONTIS PHARMA shares on October 15, 2024, and 38.3% above the three-month average closing price.

The transaction, announced today, is a strategic move by Zentiva to acquire a majority stake in the German pharmaceutical company, setting a minimum acceptance threshold of 65% of the shares. APONTIS PHARMA, known for its Single Pill combinations in the cardiovascular sector, is expected to continue its growth strategy and benefit from Zentiva’s European presence, research and production capabilities, and financial strength.

The Executive Board and Supervisory Board of APONTIS PHARMA have expressed full support for the offer, with intentions to recommend shareholders to accept it. They perceive the offer as being in the best interest of the company, including its shareholders, employees, and other stakeholders.

Steffen Saltofte, CEO of Zentiva, highlighted the offer as a pathway to providing high-quality and affordable products to an expanded customer base across Europe. Bruno Wohlschlegel, CEO of APONTIS PHARMA, sees the merger as an opportunity for more patients to access better treatments swiftly.

Zentiva has already secured about 37.5% of APONTIS PHARMA shares through an agreement with the main shareholder. The offer is contingent upon regulatory approvals and other customary conditions. Upon successful completion of the transaction, APONTIS PHARMA’s inclusion in the open market trading will be terminated, negating the need for a separate delisting offer.

Further details of the offer will be available in the offer document to be published on the internet at www.zentiva-offer.com. The offer is not subject to the German Securities Acquisition and Takeover Act, as APONTIS PHARMA is not listed on a regulated market. This news is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.